Treatment of peri-implantitis by local delivery of tetracycline. Clinical, microbiological and radiological results.
The purpose of this study was to investigate the clinical, microbiological and radiological effects of peri-implantitis therapy by local delivery of tetracycline. In 25 partially edentulous patients, 30 implants with radiographic evidence of circumferential bone loss, and peri-implant probing depths > or =5 mm were treated with polymeric tetracycline HCl-containing fibers. Clinical and microbial parameters were recorded at baseline, and 1, 3, 6, and 12 months (M) after treatment. Standardized radiographs were obtained at baseline, M3, and one year after treatment. Two patients were discontinued from the study after 180 days because of persisting active peri-implantitis with pus formation. The remaining subjects showed a significant decrease of mean peri-implant probing depth from 6.0 to 4.1 mm (M1, P<0.001), which was maintained over 12 months. In comparison to baseline, the bleeding tendency was significantly reduced after one month, and thereafter (P<0.001). No significant recession of the mucosal margin was noted. The radiologically determined distance from the shoulder of the implant to the bottom of the bony defect decreased slightly, but not significantly, from 5.2 to 4.9 mm. At M1, M3 and M6, mean total anaerobic cultivable bacterial counts were significantly lower than at baseline (P<0.001). A significant decrease in frequency of detection was noted for Prevotella intermedia/nigrescens, Fusobacterium sp., Bacteroides forsythus, and Campylobacter rectus (P<0.01). Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, and Eikenella corrodens had very low baseline frequencies that could not be significantly suppressed further. In conclusion, therapy of peri-implantitis by local delivery of tetracycline had a positive effect on clinical and microbiological parameters.
Mombelli
A
A
School of Dental Medicine, University of Geneva, 19 rue Barthélemy-Menn, CH-1211 Geneva 4, Switzerland. andrea.mombelli@nedecine.unige.ch
Feloutzis
A
A
Brägger
U
U
Lang
N P
NP
D000287:Administration, Topical; D016301:Alveolar Bone Loss / Q000000981:diagnostic imaging / Q000209:etiology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001421:Bacteria, Anaerobic / Q000187:drug effects; D001672:Biocompatible Materials / Q000008:administration & dosage*; D002482:Cellulose / Q000008:administration & dosage*; D015169:Colony Count, Microbial; D015921:Dental Implants / Q000009:adverse effects* / Q000382:microbiology; D016503:Drug Delivery Systems; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006801:Humans; D016014:Linear Models; D008297:Male; D010518:Periodontitis / Q000188:drug therapy* / Q000209:etiology* / Q000382:microbiology; D016459:Prosthesis-Related Infections / Q000188:drug therapy; D011859:Radiography; D018709:Statistics, Nonparametric; D013752:Tetracycline / Q000008:administration & dosage*
C116585:Actisite; D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D015921:Dental Implants; D002482:Cellulose; D013752:Tetracycline